Studies evaluating the effect of μOR antagonists suggest a protective action in the context of cancer, however the protection they afford is much more nuanced than merely antagonising the ORs; the pharmacokinetics and pharmacodynamics of antagonists and endogenous or exogenous agonists, and feedback on receptor expression, must be evaluated. The gene discussed is OPRM1; the disease is cancer.